Neuroblastoma is responsible for nearly 8–10% of all childhood cancers and 15% of childhood cancer mortality1
Almost 90% of cases are diagnosed in children under 5 years old1
QARZIBA® was developed in children, for children2,3
Learn more about QARZIBA® and how it could help your patients
Safety profile
See the safety profile for QARZIBA®
Contact us now
Speak with your local affiliate
Watch the QARZIBA® mode of action video
Watch now
QARZIBA® is indicated for: the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease.4
In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, QARZIBA® should be combined with interleukin-2 (IL-2).4
GL-DNB-2200032 | December 2022
References
- Esiashvili N et al. Curr Probl Cancer 2009; 33: 333–360.
- Ladenstein R et al. Lancet Oncol 2018; 19: 1617–1629.
- Ladenstein R et al. Oral Presentation. ASCO 2019.
- QARZIBA® (dinutuximab beta). Summary of product characteristics.
This is a promotional website created by Recordati Rare Diseases and is intended for HCPs only.